Download PDF
CC BY-NC-ND 4.0 · Thromb Haemost 2022; 122(06): 926-938
DOI: 10.1055/s-0041-1740254
Coagulation and Fibrinolysis

Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease

Alexander T. Cohen
1   Department of Hematological Medicine, Guy's & St. Thomas' NHS Foundation Trust, King's College London, London, United Kingdom
,
Janvi Sah
2   SIMR, LLC, Ann Arbor, Michigan, United States
,
Amol D. Dhamane
3   Bristol Myers Squibb Company, Lawrenceville, New Jersey, United States
,
Theodore Lee
4   Pfizer Inc., New York, New York, United States
,
Lisa Rosenblatt
3   Bristol Myers Squibb Company, Lawrenceville, New Jersey, United States
,
Patrick Hlavacek
4   Pfizer Inc., New York, New York, United States
,
Birol Emir
4   Pfizer Inc., New York, New York, United States
,
Rachel Delinger
2   SIMR, LLC, Ann Arbor, Michigan, United States
,
Huseyin Yuce
5   Department of Mathematics, New York City College of Technology, City University of New York, New York, New York, United States
,
Xuemei Luo
6   Pfizer Inc., Groton, Connecticut, United States
› Author Affiliations Funding This research was funded by Pfizer and Bristol Myers Squibb.
› Further Information
   Permissions and Reprints

Abstract

There has been limited evidence reported about the outcomes of oral anticoagulants among patients with venous thromboembolism (VTE) and chronic kidney disease (CKD), especially those with stage V/end-stage renal disease (ESRD). This retrospective cohort analysis of five U.S. claims databases evaluated the risk of recurrent VTE, major bleeding (MB), and clinically relevant nonmajor bleeding (CRNMB) for apixaban versus warfarin among VTE patients diagnosed with CKD, including ESRD. Inverse probability treatment weighting (IPTW) was used to balance patient characteristics between treatment cohorts. Hazard ratios (HRs) were calculated for recurrent VTE, MB, and CRNMB among patients with CKD who experienced an index VTE. An interaction analysis was conducted to evaluate treatment effects across different stages of CKD. A total of 29,790 VTE patients with CKD were selected for analyses, of whom 10,669 (35.8%) initiated apixaban and 19,121 (64.2%) initiated warfarin. Among IPTW-balanced patient cohorts, the apixaban group had significantly lower risk of recurrent VTE (HR: 0.78; 95% confidence interval [CI]: 0.66–0.92), MB (HR: 0.76; 95% CI: 0.65–0.88), and CRNMB (HR: 0.86; 95% CI: 0.80–0.93) than the warfarin group. When stratified by CKD stage (stage I/II: 8.2%; stage III: 49.4%; stage IV: 12.8%; stage V/ESRD: 12.0%; stage unspecified: 17.6%), no significant interaction was observed for effects of apixaban versus warfarin on recurrent VTE or MB. In summary, apixaban was associated with a significantly lower risk of recurrent VTE and MB than warfarin among VTE patients with CKD. CKD stages did not have significant impact on treatment effects for recurrent VTE and MB.

Keywords

chronic kidney disease - apixaban - venous thromboembolism

Author Contributions

All authors were involved in conceptualization, methodology, and writing and review of the manuscript. The statistical analysis was performed by J. Sah and R. Delinger, employees of STATinMED Research, a paid consultant to Pfizer and Bristol Myers Squibb Company.




Publication History

Received: 12 April 2021

Accepted: 10 October 2021

Article published online:
28 December 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Centers for Disease Control and Prevention.. Venous thromboembolism (blood clots): data & statistics. February 7, 2020. Accessed January 21, 2021 at: https://www.cdc.gov/ncbddd/dvt/data.html
    PubMedGoogle Scholar
  • 2 Parikh AM, Spencer FA, Lessard D. et al. Venous thromboembolism in patients with reduced estimated GFR: a population-based perspective. Am J Kidney Dis 2011; 58 (05) 746-755
    CrossrefPubMedGoogle Scholar
  • 3 Cheung KL, Zakai NA, Folsom AR. et al. Measures of kidney disease and the risk of venous thromboembolism in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) study. Am J Kidney Dis 2017; 70 (02) 182-190
    CrossrefPubMedGoogle Scholar
  • 4 Folsom AR, Lutsey PL, Astor BC, Wattanakit K, Heckbert SR, Cushman M. Atherosclerosis Risk in Communities Study. Chronic kidney disease and venous thromboembolism: a prospective study. Nephrol Dial Transplant 2010; 25 (10) 3296-3301
    CrossrefPubMedGoogle Scholar
  • 5 Wattanakit K, Cushman M, Stehman-Breen C, Heckbert SR, Folsom AR. Chronic kidney disease increases risk for venous thromboembolism. J Am Soc Nephrol 2008; 19 (01) 135-140
    Google Scholar
  • 6 Ishigami J, Grams ME, Naik RP, Coresh J, Matsushita K. Chronic kidney disease and risk for gastrointestinal bleeding in the community: the Atherosclerosis Risk in Communities (ARIC) study. Clin J Am Soc Nephrol 2016; 11 (10) 1735-1743
    CrossrefPubMedGoogle Scholar
  • 7 Ocak G, Rookmaaker MB, Algra A. et al; SMART Study Group. Chronic kidney disease and bleeding risk in patients at high cardiovascular risk: a cohort study. J Thromb Haemost 2018; 16 (01) 65-73
    CrossrefPubMedGoogle Scholar
  • 8 Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. Semin Thromb Hemost 2004; 30 (05) 579-589
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Di Minno G, Martinez J, McKean ML, De La Rosa J, Burke JF, Murphy S. Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis. Am J Med 1985; 79 (05) 552-559
    CrossrefPubMedGoogle Scholar
  • 10 Kearon C, Akl EA, Ornelas J. et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016; 149 (02) 315-352
    CrossrefPubMedGoogle Scholar
  • 11 Ortel TL, Neumann I, Ageno W. et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv 2020; 4 (19) 4693-4738
    CrossrefPubMedGoogle Scholar
  • 12 Agnelli G, Buller HR, Cohen A. et al; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369 (09) 799-808
    Google Scholar
  • 13 Bauersachs R, Berkowitz SD, Brenner B. et al; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363 (26) 2499-2510
    CrossrefPubMedGoogle Scholar
  • 14 Büller HR, Décousus H, Grosso MA. et al; Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369 (15) 1406-1415
    CrossrefPubMedGoogle Scholar
  • 15 Schulman S, Kearon C, Kakkar AK. et al; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361 (24) 2342-2352
    CrossrefPubMedGoogle Scholar
  • 16 Dawwas GK, Smith SM, Dietrich E, Lo-Ciganic WH, Park H. Comparative effectiveness and safety of apixaban versus warfarin in patients with venous thromboembolism. Am J Health Syst Pharm 2020; 77 (03) 188-195
    CrossrefPubMedGoogle Scholar
  • 17 Hanni C, Petrovitch E, Ali M. et al. Outcomes associated with apixaban vs warfarin in patients with renal dysfunction. Blood Adv 2020; 4 (11) 2366-2371
    CrossrefPubMedGoogle Scholar
  • 18 Cheung CYS, Parikh J, Farrell A, Lefebvre M, Summa-Sorgini C, Battistella M. Direct oral anticoagulant use in chronic kidney disease and dialysis patients with venous thromboembolism: a systematic review of thrombosis and bleeding outcomes. Ann Pharmacother 2021; 55 (06) 711-722
    CrossrefPubMedGoogle Scholar
  • 19 Tamariz L, Harkins T, Nair V. Mini-sentinel systematic evaluation of health outcome of interest definitions for studies using administrative data: venous thromboembolism report. Mini-Sentinel website. August 11, 2011. Accessed January 21, 2021 at: https://www.sentinelinitiative.org/sites/default/files/surveillance-tools/validations-literature/Mini-Sentinel-HOI-Evidence-Review-Venous-Thromboembolism-Report.pdf
    PubMedGoogle Scholar
  • 20 Fang MC, Fan D, Sung SH. et al. Validity of using inpatient and outpatient administrative codes to identify acute venous thromboembolism: the CVRN VTE study. Med Care 2017; 55 (12) e137-e143
    CrossrefPubMedGoogle Scholar
  • 21 Chen SY, Wu N, Gulseth M. et al. One-year adherence to warfarin treatment for venous thromboembolism in high-risk patients and its association with long-term risk of recurrent events. J Manag Care Pharm 2013; 19 (04) 291-301
    CrossrefPubMedGoogle Scholar
  • 22 Deitelzweig SB, Lin J, Kreilick C, Hussein M, Battleman D. Warfarin therapy in patients with venous thromboembolism: patterns of use and predictors of clinical outcomes. Adv Ther 2010; 27 (09) 623-633
    CrossrefPubMedGoogle Scholar
  • 23 Navaneethan SD, Jolly SE, Schold JD. et al. Development and validation of an electronic health record-based chronic kidney disease registry. Clin J Am Soc Nephrol 2011; 6 (01) 40-49
    CrossrefPubMedGoogle Scholar
  • 24 Jalal K, Anand EJ, Venuto R, Eberle J, Arora P. Can billing codes accurately identify rapidly progressing stage 3 and stage 4 chronic kidney disease patients: a diagnostic test study. BMC Nephrol 2019; 20 (01) 260
    CrossrefPubMedGoogle Scholar
  • 25 Weycker D, Li X, Wygant GD. et al. Effectiveness and safety of apixaban versus warfarin as outpatient treatment of venous thromboembolism in U.S. clinical practice. Thromb Haemost 2018; 118 (11) 1951-1961
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Hlavacek P, Guo JD, Rosenblatt L. et al. Safety, effectiveness, and health care cost comparisons among elderly patients with venous thromboembolism prescribed warfarin or apixaban in the United States Medicare population. Curr Med Res Opin 2019; 35 (12) 2043-2051
    CrossrefPubMedGoogle Scholar
  • 27 Weycker D, Wygant GD, Guo JD. et al. Bleeding and recurrent VTE with apixaban vs warfarin as outpatient treatment: time-course and subgroup analyses. Blood Adv 2020; 4 (02) 432-439
    CrossrefPubMedGoogle Scholar
  • 28 Cohen AT, Keshishian A, Lee T. et al. Effectiveness and safety of apixaban, low-molecular-weight heparin, and warfarin among venous thromboembolism patients with active cancer: a U.S. claims data analysis. Thromb Haemost 2020; 121 (03) 383-395
    PubMedGoogle Scholar
  • 29 Cunningham A, Stein CM, Chung CP, Daugherty JR, Smalley WE, Ray WA. An automated database case definition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiol Drug Saf 2011; 20 (06) 560-566
    CrossrefPubMedGoogle Scholar
  • 30 Kaatz S, Ahmad D, Spyropoulos AC, Schulman S. Subcommittee on Control of Anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 2015; 13 (11) 2119-2126
    CrossrefPubMedGoogle Scholar
  • 31 Kearon C, Ageno W, Cannegieter SC, Cosmi B, Geersing GJ, Kyrle PA. Subcommittees on Control of Anticoagulation, and Predictive and Diagnostic Variables in Thrombotic Disease. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. J Thromb Haemost 2016; 14 (07) 1480-1483
    CrossrefPubMedGoogle Scholar
  • 32 Austin PC. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med 2014; 33 (07) 1242-1258
    CrossrefPubMedGoogle Scholar
  • 33 Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med 2015; 34 (28) 3661-3679
    CrossrefPubMedGoogle Scholar
  • 34 Thoemmes F, Ong AD. A primer on inverse probability of treatment weighting and marginal structural models. Emerg Adulthood 2016; 4 (01) 40-59
    CrossrefPubMedGoogle Scholar
  • 35 Xu S, Ross C, Raebel MA, Shetterly S, Blanchette C, Smith D. Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals. Value Health 2010; 13 (02) 273-277
    CrossrefPubMedGoogle Scholar
  • 36 Winkelmayer WC, Schneeweiss S, Mogun H, Patrick AR, Avorn J, Solomon DH. Identification of individuals with CKD from Medicare claims data: a validation study. Am J Kidney Dis 2005; 46 (02) 225-232
    CrossrefPubMedGoogle Scholar